DA
VYNE icon

DSC Advisors’s VYNE Therapeutics VYNE Stock Holding History

DSC Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.31M Hold
696,465
– – 11.93% 3
2024
Q2 		$1.37M Hold
696,465
– – 4.58% 5
2024
Q1 		$2.14M Hold
696,465
– – 3.42% 7
2023
Q4 		$1.62M Buy
696,465
+581,465
+506% +$1.81M 2.68% 7
2023
Q3 		$460K Hold
115,000
– – 0.59% 15
2023
Q2 		$467K Hold
115,000
– – 0.7% 11
2023
Q1 		$354K Buy
115,000
+27,778
+32% +$99.7K 0.31% 12
2022
Q4 		$236K Sell
87,222
-61,111
-41% -$244K 0.54% 12
2022
Q3 		$596K Hold
148,333
– – 0.61% 28
2022
Q2 		$1.04M Hold
148,333
– – 1.04% 17
2022
Q1 		$1.74M Buy
148,333
+6,611
+5% +$78.6K 0.6% 17
2021
Q4 		$2.6M Buy
141,722
+80,611
+132% +$1.73M 2.01% 10
2021
Q3 		$1.53M Hold
61,111
– – 1.55% 14
2021
Q2 		$3.86M Buy
61,111
+3,436
+6% +$272K 2.79% 12
2021
Q1 		$7.11M Hold
57,675
– – 4.4% 7
2020
Q4 		$6.56M Hold
57,675
– – 5.42% 7
2020
Q3 		$6.89M Sell
57,675
-2,867
-5% -$335K 4.61% 7
2020
Q2 		$7.54M Buy
60,542
+31,712
+110% +$4.29M 8.27% 6
2020
Q1 		$5.56M Buy
+28,830
New +$9.04M 5.43% 8

Other funds holding VYNE

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

DSC Advisors's VYNE Position: Q3 2024 in Review

DSC Advisors held its VYNE Therapeutics (VYNE) position steady in Q3 2024 at 696,465 shares worth $1.31M. The position accounts for 11.93% of the portfolio, ranked #3.

DSC Advisors first reported a position in VYNE in Q1 2020 and has held it in 19 quarters since. The position peaked at $7.54M in Q2 2020. 33 funds tracked by Wall St. Rank hold VYNE as of Q3 2024.

  • DSC Advisors held 696,465 shares of VYNE Therapeutics worth $1.31M as of Q3 2024.
  • DSC Advisors left its VYNE Therapeutics share count unchanged in Q3 2024.
  • VYNE Therapeutics made up 11.93% of DSC Advisors's portfolio in Q3 2024, its #3 holding.
  • DSC Advisors first reported a position in VYNE Therapeutics in Q1 2020 and has held it in 19 quarters since.
  • DSC Advisors's VYNE Therapeutics position peaked at $7.54M in Q2 2020.
  • 33 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2024.

Based on DSC Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.